Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...
Germany’s Formycon has decided today to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback